Schildkliercarcinoom subtypes
Incidentie: 600 patiënten per jaar.
Subtypes:
- Gedifferentieerd (tumormarker = thyreoglobuline)
- NIFTP: non-invasive follicular thyroid neoplasm with papillary-like nuclear features,
- Papillair,
- Folliculair,
- Hürthle cell,
- Slecht gedifferentieerd.
- Medullair (tumormarker = calcitonine en CEA),
- 20-30% erfelijk, m.n. MEN2 syndroom.
- Anaplastisch: ongedifferentieerd schildkliercarcinoom.
Tumorsoorten
Literatuur
Referenties
- Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 2014;384:319-28.
- Sorafenib bij het lokaal gevorderd of gemetastaseerd jodium-refractair gedifferentieerd schildkliercarcinoom. advies commissie BOM november 2014.
- Final overall survival analysis of patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) treated with sorafenib in the phase 3 DECISION trial: An exploratory crossover adjustment analyses. abstract 953PD. Annals of Oncology 27 (Supplement 6): vi328–vi350, 2016.
- Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. The New England journal of medicine 2015;372:621-30.
- Lenvatinib bij het lokaal gevorderd of gemetastaseerd jodium-refractair gedifferentieerd schildkliercarcinoom. Advies commissie BOM juni 2016.
- Drilon A, Laetsch TW, Kummar S, et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. The New England journal of medicine 2018;378:731-9.
- Libretto-001 study. unpublished.
- Wells SA, Jr., Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30:134-41.
- Vandetanib bij het lokaal gevorderd of gemetastaseerd medullair schildkliercarcinoom. advies commissie BOM maart 2013.
- Elisei R, Schlumberger MJ, Muller SP, et al. Cabozantinib in progressive medullary thyroid cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31:3639-46.
- Cabozantinib bij het lokaal gevorderd of gemetastaseerd medullair schildkliercarcinoom. Advies commissie BOM april 2015.
- Schlumberger M, Elisei R, Muller S, et al. Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma. Annals of oncology : official journal of the European Society for Medical Oncology 2017;28:2813-9.
- Subbiah V, Kreitman RJ, Wainberg ZA, et al. Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018;36:7-13.
- Smallridge RC, Ain KB, Asa SL, et al. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 2012;22:1104-39.